RWTH Aachen University Hospital, Germany
Postdoctoral researcher
Quim Peña obtained his PhD degree in Chemistry from the Universitat Autònoma de Barcelona (Spain) and Aix-Marseille Université (France) in 2019, focusing on the design and study of metal-based anticancer compounds. Since 2020, he is a postdoctoral researcher in the Department of Nanomedicine and Theranostics at the Institute for Experimental Molecular Imaging at RWTH Aachen University Hospital (Uniklinik RWTH Aachen). His research focuses on the use of prodrug chemistry and nanotechnology for improved delivery of bioactive metals and (metal-based) drugs, with the aim of enhancing (immuno-)therapy efficacy, treatment tolerability and, ultimately, promoting clinical translation.
Quim is currently part of the management committee of a European COST Action Grant (EU4MOFs), and he is involved in multiple scientific societies, including the Spanish Royal Society of Chemistry (RSEQ), the Spanish Association of Bioinorganic Chemistry (AEBIN), the European Society for Molecular Imaging (ESMI) and the Controlled Release Society (CRS). He is strongly committed to promote transparent, high-quality and cooperative scientific work, embracing new challenges and engaging in multi- and inter-disciplinary synergies in order to truly create progress beyond the state-of-the-art and generate societal impact. As an active member of the CRS, and now also of the YSC, he does not only aim to help the drug delivery community continue to grow, but also support new, younger generations of scientists, both professionally and personally.
